Welcoming Dr. Kumanan Wilson as the Interim CEO of the Bruyère Research Institute
Please join us in welcoming Dr. Kumanan Wilson as the incoming Interim CEO and Chief Scientific Officer (CSO) of the Bruyère Research Institute and Vice President Research and Academic Affairs for Bruyère. Dr. Wilson has an extensive and impressive track record as a scientist and Clinical Research Chair, innovator, specialist in general internal medicine, and founder of CANImmunize.
Along with being an investigator with the Bruyère Research Institute, Dr. Wilson has also held the role of Scientific Advisor in Innovation for Bruyère and the Research Institute for over 3 years. In his advisor role he has mentored and supported other investigators and innovators to successfully apply for research funding and has been an expert source of evidence and guidance related to COVID-19.
Dr. Wilson brings expertise in digital health, immunization, public health, and Big Data and an interest in health ethics, law, and policy. His passion lies in working with other scientists, clinicians, and partners to bring their ideas into practice, combining science, data, development, and design. Dr. Wilson also works with teams to bring digital solutions to patients, clinicians, business, government, and the general public, all with the vision to improve the health system and the experiences of those in it.
Dr. Wilson’s term came into effect on November 1, 2022, providing overlap and handover with CEO, Heidi Sveistrup, PhD. The reins were officially turned over on December 1, 2022 at our annual Research Day.
We are excited to bring in the new year with Kumanan and are grateful to Heidi for her tremendous contribution over the past six years.